Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide.
Wassim AbidaAndrew W HahnNeal D ShoreArchana M AgarwalPaul R SieberMatthew R SmithTanya Barauskas DorffJ Paul MonkMatthew B RettigRupal PatelAnne PageMaureen DuffRongda XuJian WangShravani R BarkundAleksandr PankovAmber WangMelissa R JunttilaPratik S MultaniAnneleen DaemenEdna Chow-ManevalChristopher L LogothetisMichael J MorrisPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Although the combination of ORIC-101 and enzalutamide demonstrated an acceptable tolerability profile, GR target inhibition with ORIC-101 did not produce clinical benefit in men with metastatic prostate cancer resistant to enzalutamide.